Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
09/06/202318h33Edgar (US Regulatory)Schedule 13g
(sc 13g/a)
NYSE:TEVATeva Pharmaceutical Industries Ltd
09/06/202316h39Dow Jones NewsNY AG Lands Final Approval for $17.3 Billion Opioid SettlementNYSE:TEVATeva Pharmaceutical Industries Ltd
08/06/202315h27Dow Jones NewsTeva Pharma Reaches Opioid Settlement With Nevada, the Final State to Resolve ClaimsNYSE:TEVATeva Pharmaceutical Industries Ltd
08/06/202314h31Edgar (US Regulatory)Current Report Filing (8-k)NYSE:TEVATeva Pharmaceutical Industries Ltd
08/06/202314h30Business WireTeva Concludes Nationwide Opioids Settlement AgreementNYSE:TEVATeva Pharmaceutical Industries Ltd
06/06/202314h00Business WirePhil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma ManagementNYSE:TEVATeva Pharmaceutical Industries Ltd
02/06/202322h30Business WireTeva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023NYSE:TEVATeva Pharmaceutical Industries Ltd
24/05/202322h29Edgar (US Regulatory)Specialized Disclosure Report (sd)NYSE:TEVATeva Pharmaceutical Industries Ltd
24/05/202322h16Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NYSE:TEVATeva Pharmaceutical Industries Ltd
20/05/202317h00Business WireTeva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
18/05/202314h30Business WireTeva Launches New “Pivot to Growth” StrategyNYSE:TEVATeva Pharmaceutical Industries Ltd
15/05/202314h00Business WireAUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now Available in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
10/05/202322h05Edgar (US Regulatory)Quarterly Report (10-q)NYSE:TEVATeva Pharmaceutical Industries Ltd
10/05/202313h00Business WireTeva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP OutlookNYSE:TEVATeva Pharmaceutical Industries Ltd
09/05/202313h00Business WireTeva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding Several ESG Targets Ahead of ScheduleNYSE:TEVATeva Pharmaceutical Industries Ltd
03/05/202314h30Business WireU.S. Mental Health Access Program Expands Medicine Donation to Seven New StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
29/04/202302h22Business WireTeva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in AdultsNYSE:TEVATeva Pharmaceutical Industries Ltd
29/04/202302h22Business WireTeva et MedinCell annoncent l'approbation par la FDA américaine de UZEDY™ (risperidone), un antipsychotique sous forme de suspension injectable sous-cutanée à libération prolongée pour le traitement de la schizophrénie chez l'adulteNYSE:TEVATeva Pharmaceutical Industries Ltd
27/04/202314h35Business WireTeva to Launch New Growth Strategy at Investor DayNYSE:TEVATeva Pharmaceutical Industries Ltd
19/04/202322h18Edgar (US Regulatory)Annual Report to Security Holders (ars)NYSE:TEVATeva Pharmaceutical Industries Ltd
14/04/202322h15Business WireTeva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023NYSE:TEVATeva Pharmaceutical Industries Ltd
14/04/202320h28Dow Jones NewsTeva Shares Drop 11% After Alvotech Gets FDA Complete Response LetterNYSE:TEVATeva Pharmaceutical Industries Ltd
14/04/202302h53Business WireComplete Response Letter Received for AVT02 Biologics License ApplicationNYSE:TEVATeva Pharmaceutical Industries Ltd
11/04/202314h00Business WireTeva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
27/03/202314h00Business WireTeva’s Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integration with a Large U.S. Health SystemNYSE:TEVATeva Pharmaceutical Industries Ltd
13/03/202314h33Business WireTeva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election of Early SettlementNYSE:TEVATeva Pharmaceutical Industries Ltd
09/03/202314h00Business WireTeva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide capsules), in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
08/03/202322h06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:TEVATeva Pharmaceutical Industries Ltd
07/03/202322h00Business WireTeva to Present at the Barclays Global Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
03/03/202313h03Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA